Zymeworks Stock News

This move is a reversal from the hour prior, which saw price move up. The post Zymeworks Inc (ZYME): Price Now Near $20.12; Daily Chart Shows Downtrend on 50 Day Basis appeared first on ETF Daily News .

Wall Street brokerages expect Zymeworks Inc. (NYSE:ZYME) to report $11.19 million in sales for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Zymeworks earnings, with the highest sales estimate coming in at $22.00 million and the lowest estimate coming in at $2.50 million. Zymeworks posted sales of $15.68 million in the []

Zymeworks Inc. (NYSE:ZYME) traded at $19.38 at close of the session on Monday, 11/29/21, made a downward move of -0.62% on its previous days price. Looking at the stock we see that its previous close was $19.50 and the beta (5Y monthly) reads 0.97 with the days price range being $19.26 $20.00. In terms Why Zymeworks Inc. Stock Might Make Sense If Bought Today Read More »

Vanguard Group Inc. raised its stake in Zymeworks Inc. (NYSE:ZYME) by 26.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 165,214 shares of the companys stock after buying an additional 34,969 shares during the period. Vanguard Group Inc.s holdings in Zymeworks were worth []

SVB Leerink restated their hold rating on shares of Zymeworks (NYSE:ZYME) in a report published on Monday, Price Targets.com reports. They currently have a $43.00 price objective on the stock. SVB Leerink also issued estimates for Zymeworks FY2024 earnings at ($5.76) EPS and FY2025 earnings at ($4.32) EPS. ZYME has been the subject of a []

Zymeworks (NYSE:ZYME)s stock had its hold rating reiterated by stock analysts at SVB Leerink in a report issued on Monday, Analyst Ratings Network reports. They currently have a $43.00 target price on the stock. SVB Leerinks price objective indicates a potential upside of 116.19% from the companys current price. SVB Leerink also issued estimates for []

Related Stocks: YY , SLAM , ZYME , LIDR , EVGO , OUST , WB , WORK , ALXN , MXIM , GNW , PACE , SVAC ,

Northern Trust Corp boosted its position in Zymeworks Inc. (NYSE:ZYME) by 506.9% during the 2nd quarter, HoldingsChannel.com reports. The firm owned 246,207 shares of the companys stock after purchasing an additional 205,639 shares during the quarter. Northern Trust Corps holdings in Zymeworks were worth $8,541,000 at the end of the most recent reporting period. A []

Weiss Multi Strategy Advisers LLC lifted its stake in shares of Zymeworks Inc. (NYSE:ZYME) by 3.7% in the 2nd quarter, HoldingsChannel reports. The firm owned 17,077 shares of the companys stock after buying an additional 612 shares during the quarter. Weiss Multi Strategy Advisers LLCs holdings in Zymeworks were worth $592,000 as of its most []

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will p

Zymeworks Inc. (ZYME) delivered earnings and revenue surprises of -5.93% and -50.03%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will ho

Zymeworks (ZYME) has been struggling lately, but the selling pressure may be coming to an end soon.